Bone Therapeutics

Bone Therapeutics S.a.

Enrico Bastianelli Sprl

UniversitÉ Libre De Bruxelles

Universitéde Liége

Centre Hospitalier Universitaire De Liège

Theravet Sa

Enrico Bastianelli

Chris Vervaet

Pierre Attali

Isabelle Tytgat

Valentina Albarani

Pierre-Yves Laruelle

Sabrina Ena

Xuan Mai Nguyen

Sandra Pietri

Xavier Pesesse

Cindy Badoer

Elodie Deltour

Christelle Bizimungu

Dominique De Seny

Michel Malaise

Valérie Gangji

Carmen Brenner

Delphine Spruyt

Sabrina Rigutto

Aude Ingels

Myrielle Mathieu

Jean-Philippe Hauzeur

Caroline Zeippen

Julie Winand

The invention concerns pharmaceutical formulations comprising solvent/detergent (S/D)-treated plasma and a glycosaminoglycan such as hyaluronic acid, and their use for treating diseases, particularly musculoskeletal diseases.

Formulations involving solvent/detergent-treated plasma (S/D plasma) and uses thereof

The application discloses a method for obtaining MSC-derived cells with improved transplantation properties from MSC, the method comprising a cell size reduction step, wherein said cell size reduction step is characterized by contacting MSC or MSC-derived cells in vitro or ex vivo with heparin or a derivative or analogue thereof at a concentration of at least 0.01 IU/ml. The application further provides a method for obtaining mesenchymal stem cell-derived cells from mesenchymal stem cells (MSC) comprising contacting MSC in vitro or ex vivo with FGF-2, TGF&#x3b2; and at least 0.01 IU/ml heparin or a derivative or analogue thereof. The invention also provides the so-obtained cells and cell populations, as well as further products comprising such and uses thereof.

Methods for differentiating mesenchymal stem cells

An intra-articular pharmaceutical composition is used for the treatment and/or the prevention of acute or chronic osteoarticular diseases and acute or chronic osteoarticular symptoms especially osteoarthritis. The composition includes a possibly adequate pharmaceutical carrier or diluent, a glycosaminoglycan, a compound activating the alpha 2 adrenergic receptor, an anti-inflammatory agent and stem cells.

Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases

A pharmaceutical composition for the acute and/or chronic treatment or prevention of osteoarticular diseases includes an adequate pharmaceutical carrier or diluent, a polysaccharide and/or a glycosaminoglycan, an anti-inflammatory agent and stem cells.

Pharmaceutical composition for use in the treatment or prevention of osteoarticular diseases

The invention relates to a new type of mesenchymal stem cells (MSC) which co-express at least one mesenchymal marker, preferably at least CD105 and CD34. Also provided are bone-forming cells having an analogous phenotype. The invention also provides the cells and cell populations, as well as further products comprising such and uses thereof in bone therapy.

Mesenchymal stem cells and bone-forming cells

Growing community of inventors

Rhode-Saint-Genese, Belgium

Enrico Bastianelli